Edition:
United States

Celgene Corp (CELG.O)

CELG.O on Nasdaq

112.66USD
20 Jan 2017
Change (% chg)

$0.00 (+0.00%)
Prev Close
$112.66
Open
--
Day's High
--
Day's Low
--
Volume
87
Avg. Vol
4,571,819
52-wk High
$127.00
52-wk Low
$93.05

Latest Key Developments (Source: Significant Developments)

Celgene Corp appoints Mark Alles CEO, effective March 1, 2016
Thursday, 11 Feb 2016 07:30am EST 

Celgene Corp:Effective March 1, 2016, Mark Alles will be promoted to chief executive officer, with Bob Hugin assuming the executive chairman role.  Full Article

Celgene Corp expands eight-year technology relationship with Medidata Solutions Inc
Wednesday, 10 Feb 2016 06:30am EST 

Medidata Solutions Inc:Celgene expands relationship with Medidata in enterprise clinical trial technology.Says Celgene Corporation expanded its eight-year technology relationship with Medidata.  Full Article

Celgene Corp announces leadership changes
Monday, 11 Jan 2016 11:06am EST 

Celgene Corp:Organizational changes strengthen leadership team and position Celgene for long-term growth.Says Mark Alles to be promoted to Chief Executive Officer.Says Bob Hugin to continue to lead strategic direction of company in the role of Executive Chairman.Says Jacqualyn Fouse, to be promoted to President & Chief Operating Officer.Says Scott Smith, President immunology & inflammation, will assume an expanded leadership role.Says alles has been with Celgene since 2004, most recently serving as president & COO.  Full Article

Inception IBD Inc and Celgene Corp enter strategic collaboration to advance novel therapeutics for inflammatory bowel disease
Thursday, 10 Dec 2015 08:00am EST 

Inception IBD Inc:Co and Celgene enter strategic collaboration to advance novel therapeutics for inflammatory bowel disease.under terms, Inception ibd is eligible to receive up to US$40 million in cash payments during the course of the collaboration.  Full Article

Celgene in Collaboration with Astrazeneca Announce Initiation of Fusion Clinical Development Program in Immuno-Oncology
Monday, 7 Dec 2015 07:30am EST 

Celgene Corp and AstraZeneca:Announced the initiation of the FUSION clinical development program of durvalumab (MEDI4736), an investigational human monoclonal antibody directed against programmed cell death ligand 1 (PD-L1) in hematologic disorders.FUSION program is part of a strategic collaboration with AstraZeneca and its global biologics research and development arm MedImmune, to develop and commercialize durvalumab across a range of blood cancers including non-Hodgkin's lymphoma, myelodysplastic syndromes and multiple myeloma.  Full Article

Celgene Corporation and Acceleron Pharma Inc announces FDA granted Fast Track Designation to luspatercept for treatment of anemia
Monday, 7 Dec 2015 07:00am EST 

Celgene Corporation and Acceleron Pharma Inc:Announced that the United States Food and Drug Administration (FDA) has granted Fast Track Designation to luspatercept for the treatment of anemia in patients with lower-risk myelodysplastic syndromes (MDS).Fast Track program of the FDA is designed to facilitate the development, and expedite the review, of new drugs that are intended to treat serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs.  Full Article

Celgene VIDAZA (Azacitidine for Injection) approved by European Commission as new treatment for elderly patients with acute myeloid leukaemia
Friday, 30 Oct 2015 03:00am EDT 

Celgene International Sàrl, a wholly owned subsidiary of Celgene Corporation:Says that European Commission (EC) has approved VIDAZA (azacitidine for injection) for the treatment of adult patients aged 65 years or older with acute myeloid leukaemia (AML) who are not eligible for haematopoietic stem cell transplantation (HSCT).Says VIDAZA Marketing Authorisation has been updated to include this new indication in AML, covering patients who have >30% myeloblasts according to the WHO classification; previously, the indication covered AML patients with <30% blasts.  Full Article

Celgene Corp announces detailed results from maintenance phase of TOUCHSTONE phase 2 clinical trial of Ozanimod
Monday, 19 Oct 2015 08:00am EDT 

Celgene Corp:phase 2 maintenance data from oral ozanimod touchstone study in ulcerative colitis presented at acg plenary session.Says week 32 safety results consistent with those at week 8.Says clinical response and mucosal healing also significantly improved with ozanimod 1 mg compared to placebo at week 32.Twenty one percent of patients on ozanimod 1 mg achieved or maintained clinical remission at week 32 compared with 6 percent on placebo.  Full Article

Celgene Corporation says Celgene International Sàrl's VIDAZA (Azacitidine for Injection) receives positive CHMP opinion
Friday, 25 Sep 2015 03:00am EDT 

Celgene International Sàrl:Says that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion.Positive opinion for an expanded indication of VIDAZA(azacitidine for injection) for the treatment of adult patients aged 65 years or older with acute myeloid leukaemia (AML) who are not eligible for haematopoietic stem cell transplantation (HSCT).Celgene International Sàrl is a wholly owned subsidiary of Celgene Corporation.  Full Article

Celgene and Nurix announce collaboration targeting protein homeostasis
Wednesday, 16 Sep 2015 07:00am EDT 

Celgene Corp:Celgene and nurix announce collaboration targeting protein homeostasis for next-generation therapies in oncology, inflammation and immunology.Nurix inc says under the terms of the collaboration, Celgene will make an upfront payment to nurix of $150 million.Nurix inc says deal also includes an undisclosed equity investment, option to license future programs.Nurix inc says nurix will control and is responsible for all drug discovery and development activities through the end of phase 1 clinical trials.Nurix, inc-Celgene may license global development and commercialization rights to a program in exchange for payments totaling up to $405 million.Nurix, inc-Celgene will have worldwide rights to collaboration products, with the exception of certain collaboration products.  Full Article

BRIEF-Medidata Solutions says Celgene increased adoption of Medidata Clinical Cloud

* Medidata Solutions - Celgene increases adoption of Medidata Clinical Cloud Source text for Eikon: Further company coverage: